雌激素受体阴性孕激素受体阳性乳腺癌研究进展  

Analysis on the causes of estrogen receptor-negative and progesterone receptor-positive breast cancer

作　　者：杜艳茹 宣立学 应建明 Du Yanru;Xuan Lixue;Ying Jianming(Department of Pathology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Department of Breast Surgery,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China)

机构地区：[1]国家癌症中心,国家肿瘤临床医学研究中心,中国医学科学院北京协和医学院肿瘤医院病理科,100021 [2]国家癌症中心,国家肿瘤临床医学研究中心,中国医学科学院北京协和医学院肿瘤医院乳腺外科,100021

出　　处：《中华内分泌外科杂志》2021年第2期202-204,共3页Chinese Journal of Endocrine Surgery

基　　金：国家重点研发计划 (2017YFC1311005);院校基本科研业务项目(2019HX320067)。

摘　　要：乳腺癌病理学亚型可根据其免疫组化结果如雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)、人表皮生长因子受体2(human epidermal growth factor receptor2,HER2)及Ki67表达进一步细分为不同的分子亚型,包括管腔型、HER2过表达型和三阴型。管腔型被定义为ER和(或)PR阳性,在分子机制上,ER的表达活性可调控PR表达,所以ER与PR表达通常一致,但在检测过程中,往往会出现一部分ER/PR表达不一致的情况,尤其是ER(-)/PR(+),但关于此类病例是否真实存在尚存争议,应对此型患者重新进行ER和PR免疫组化检测,再根据HER2状态进行分类。因ER与PR的表达与乳腺癌的内分泌治疗疗效密切相关,故其检测结果将直接影响临床医生对治疗方案的选择。本文现就ER(-)/PR(+)型乳腺癌存在的原因及机制研究进展进行文献复习探讨。The pathological subtypes of breast cancer can be further divided into different molecular subtypes based on their immunohistochemical staining,such as estrogen receptor(ER),progesterone receptor(PR),human epidermal growth factor receptor2(HER2)and Ki67 expression,including luminal subtype,HER2 overexpression subtype and triple negative subtype.The luminal subtype is defined as ER and/or PR positive.In molecular mechanism,the expression activity of ER can regulate the expression of PR,so the expression of ER and PR is usually consistent.However,in the process of detection,some breast cancers with inconsistent ER/PR expression often appear,especially those with ER(-)/PR(+).There is still controversy about whether such cases are true.Patients with this type of breast cancer should be subjected to ER and PR immunohistochemical staining again,and then reclassified according to HER2 status.The expression of ER/PR is closely related to the efficacy of endocrine therapy for breast cancer,so its test results will directly affect the treatment options of clinician.This article will review and discuss the research progress of the causes and mechanisms of ER(-)/PR(+)breast cancer.

关 键 词：乳腺癌 雌激素受体 孕激素受体 

分 类 号：R655.8[医药卫生—外科学] R737.9[医药卫生—临床医学]